Business Information
The group's principal activities are the research, development and marketing of medicines for serious health conditions. The group focused on seven important areas of healthcare such as gastrointestinal, cardiovascular, oncology, respiratory and inflammation, central nervous system, pain control and infection. The group has 31 manufacturing sites in 20 countries. Brands include losec/prilosec, nexium, seloken/toprol-xl, plendil, zoladex, casodex, arimidex, nolvadex, pulmicort, oxis, symbicort, accolate, rhinocort, seroquel, zomig, diprivan, naropin, xylocaine, atacand, zestril, and merrem/meronem. The group operates in the United Kingdom, Belgium, France, Germany, Italy, Spain, Sweden, the Netherlands, Canada, Puerto Rico, the United States of America, Australia and Japan.
|
|
Name |
Title
|
Email
|
| Hakan Mogren | Non - Exec. Dep. Chmn. | N/A | | Louis Schweitzer | Non - Exec. Chmn. | N/A | | David Mott | CEO - Medimmune | N/A | | Jonathan Symonds | Exec. Dir., CFO | N/A | | Simon Lowth | Exec. Dir., CFO | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 26,475,000 | 4,392,000 | | 2005 | 23,950,000 | 3,884,000 | | 2004 | 21,960,000 | 3,051,000
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
